NCT00357773View on ClinicalTrials.gov

Efficacy and Safety of T1225 1.5% Versus Tobramycin 0.3 % in the Treatment of Purulent Bacterial Conjunctivitis

PHASE3CompletedINTERVENTIONAL
Timeline

Start Date

May 31, 2004

Study Completion Date

June 30, 2005

Conditions
Conjunctivitis, Bacterial
Interventions
DRUG

Azithromycin (T1225)

Sponsors

Lead Sponsor

Laboratoires Thea
All Listed Sponsors
lead

Laboratoires Thea

INDUSTRY